The Federal Trade Commission is investigating Canonsburg, Pa.-based Mylan for allegedly violating antitrust laws by blocking EpiPen competitors from reaching the market, reports Bloomberg.
The drugmaker received a request for information from the FTC as part of a preliminary investigation, Mylan told Bloomberg Monday.
The FTC will investigate whether Mylan improperly extended EpiPen patents by making small, unnecessary changes to the device to block generic competition, a source told Bloomberg. The agency will also assess whether Mylan entered any agreements that delayed cheaper versions of the EpiPen from entering the market, the unnamed source said.
A Mylan spokesperson said the company has not acted improperly to prevent generic competition, according to the report.
The investigation is still in its early stages and may not result in an enforcement action, the unnamed source told Bloomberg.
More articles on supply:
Viewpoint: Why a Silicon Valley mindset is wrong for the FDA
Amazon seeks legal options to counter immigration ban: 4 things to know
Senate Dems: Hiring freeze could stall 21st Century Cures Act